$BMY
Bristol-Myers Squibb Company · NYSE · Healthcare
- Market cap
- 125.59B
- Volume
- 9.76M
- P/E
- 13.54
- Day range
- 61.31 – 62.84
- 52w range
- 42.52 – 68.64
- Analyst target
- 65.42
AI Summary
Generating a unique summary for BMY…
AI-generated for information only — not investment advice.
Share this ticker
$BMY -2.41% at 61.48 Ken Griffin and 1 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/BMY
Company summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Institutional ownership
Institutions hold 84.84% · insiders 0.10% · 3,293 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 180.38M | $11.09B | 8.83% | 2026-06-30 |
| Vanguard Capital Management LLC | 133.34M | $8.20B | 6.53% | 2026-06-30 |
| State Street Corporation | 102.41M | $6.30B | 5.01% | 2026-06-30 |
| JPMORGAN CHASE & CO | 71.71M | $4.41B | 3.51% | 2026-06-30 |
| Charles Schwab Investment Management, Inc. | 67.60M | $4.16B | 3.31% | 2026-06-30 |
| Geode Capital Management, LLC | 56.44M | $3.47B | 2.76% | 2026-06-30 |
| Vanguard Portfolio Management LLC | 46.87M | $2.88B | 2.29% | 2026-06-30 |
| NORGES BANK | 36.87M | $2.27B | 1.80% | 2026-06-30 |
| Bank of America Corporation | 34.05M | $2.09B | 1.67% | 2026-06-30 |
| Price (T.Rowe) Associates Inc | 31.71M | $1.95B | 1.55% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| GALLMAN CARI | General Counsel | — | 4.6K | 2026-10-02 |
| MASSACESI CRISTIAN | Officer | Sale at price 64.57 per share. | 6.2K | 2026-09-09 |
| SHORT BARTIE WENDY | Officer | Conversion of Exercise of derivative security at price 66.92 per share. | 1.2K | 2026-09-01 |
| HOLZER PHIL M | Officer | Sale at price 67.50 per share. | 500.00 | 2026-08-25 |
| MASSACESI CRISTIAN | Officer | — | 51.2K | 2026-07-31 |
| GALLMAN CARI | General Counsel | — | 1.1K | 2026-07-31 |
| HALLER JULIA A | Director | Conversion of Exercise of derivative security at price 53.76 per share. | 20.5K | 2026-06-15 |
| SHORT BARTIE WENDY | Officer | — | 8.0K | 2026-06-03 |
| LENKOWSKY ADAM | Officer | — | 1.4K | 2026-05-01 |
| SHANAHAN KARIN | Officer | — | 3.3K | 2026-04-01 |
| ELKINS DAVID VINCENT | Chief Financial Officer | Sale at price 61.60 - 62.05 per share. | 30.0K | 2026-04-01 |
| ELKINS DAVID VINCENT | Chief Financial Officer | — | 63.0K | 2026-03-10 |
Analyst ratings
Consensus score 2.50 (1 = strong buy, 5 = sell) · mean target 65.42
- Wells FargoEqual-Weightmain2026-10-13
- Cantor FitzgeraldNeutralmain2026-10-08
- Morgan StanleyUnderweightmain2026-10-07
- Leerink PartnersMarket Performdown2026-10-05
- Piper SandlerOverweightreit2026-09-16
- HSBCHoldmain2026-09-10
- Argus ResearchBuyup2026-08-05
- CitigroupNeutralmain2026-08-03
- RBC CapitalSector Performmain2026-07-31
- JP MorganOverweightmain2026-07-31
Earnings
Next report: 2026-10-29
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | 1.63 | 1.52 | 0.11 |
| 4Q2025 | 1.26 | 1.20 | 0.06 |
| 1Q2026 | 1.58 | 1.42 | 0.16 |
| 2Q2026 | 2.04 | 1.60 | 0.44 |
SEC filings
- 10-QPeriodic Financial Reports2026-07-30Open
- 11-KAnnual report of employee stock purchase2026-06-05Open
- 8-KCorporate Changes & Voting Matters2026-05-08Open
- 8-KCorporate Changes & Voting Matters2026-04-30Open
- DEFA14AProxy Statements2026-04-17Open
- 15-12GNotice of termination of registration of a class of securities under Section 12(g)2026-03-27Open
- DEF 14AProxy Statements2026-03-25Open
- 10-KPeriodic Financial Reports2026-02-11Open
- 8-KCorporate Changes & Voting Matters2026-02-05Open
- 8-KCorporate Changes & Voting Matters2026-01-12Open
Latest BMY news
- The Call Bristol-Myers Squibb Bulls Got Right
If you had been weighing Bristol-Myers Squibb against its looming patent cliffs and the promise of late-stage oncology drugs back in October 2025, the result now looks very different on paper. Holding Bristol-Myers Squibb over the past year would have returned 46.5%, including dividends. The question is simple: faced with aging demographics, genomics-driven treatments and debt concerns, what did early buyers think would matter most for this business? Narratives are how investors here put a...
Sun, 25 Oct 2026 01:13:05 +0000
- Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Bristol Myers Squibb (BMY) reached $61.48 at the closing of the latest trading day, reflecting a -2.41% change compared to its last close.
Fri, 23 Oct 2026 20:45:02 +0000
- BMY Stock Falls 2% After Patient Death In Early Multiple Sclerosis CAR T Trial
The death of the patient with highly active relapsing MS occurred after the study’s data cutoff.
Fri, 23 Oct 2026 19:48:18 +0000
- Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data
Key TakeawaysTempus AI shares rose 6% today after Bristol Myers Squibb agreed to license Tempus’s oncology data through 2031 and use its Lens AI platform. Bristol Myers Squibb is a returning customer committing for years, which suggests Tempus’s data is the real edge in its business.
Fri, 23 Oct 2026 19:22:38 +0000
- Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
PRINCETON, N.J., October 23, 2026--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients...
Fri, 23 Oct 2026 14:30:00 +0000
- Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
NEW YORK, October 23, 2026--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, "BMS") and Tempus AI, Inc. (NASDAQ: TEM, "Tempus") to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions. BMS also leads Pathos’s Series E financing and gains access to Pathos Foundry across its broader R&D portfolio
Fri, 23 Oct 2026 13:00:00 +0000
- Tempus Expands Strategic Collaboration with Bristol Myers Squibb
CHICAGO, October 23, 2026--Tempus AI, Inc. (NASDAQ: TEM, "Tempus") today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, "BMS"), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest l
Fri, 23 Oct 2026 13:00:00 +0000
- 3 Defensive Stocks to Buy as the AI Selloff Rattles Wall Street
The recent AI sell-off shows why diversification matters. Here are three stocks that can help investors diversify their portfolios.
Fri, 23 Oct 2026 11:30:02 +0000